The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).
 
Andrew J. Armstrong
Honoraria - Dendreon; Janssen Oncology; Sanofi
Consulting or Advisory Role - Bayer; Dendreon; Janssen Biotech; Medivation; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Dendreon; Sanofi
Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Bayer; Dendreon; Janssen Biotech; Medivation; Sanofi
 
Susan Halabi
Consulting or Advisory Role - Bayer; Eisai; Tokai Pharmaceuticals
Travel, Accommodations, Expenses - Bayer
 
Jun Luo
Honoraria - Gilead Sciences; Sanofi
Consulting or Advisory Role - Janssen Oncology; Sun Pharma; Tokai Pharmaceuticals
Research Funding - Astellas Pharma (Inst); Gilead Sciences (Inst); Mirati Therapeutics (Inst); Orion Pharma GmbH (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Jun Luo is a co-inventor of a technology assigned to Johns Hopkins University who licensed to Tokai Pharmaceuticals. (Inst); Jun Luo is a co-inventor of a technology licensed to Qiagen (Inst)
 
David M. Nanus
Consulting or Advisory Role - Roche/Genentech
 
Paraskevi Giannakakou
Employment - Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
Research Funding - Sanofi
Patents, Royalties, Other Intellectual Property - International Patent Application DOCKET NO. 1676.083WO1 “Identifying Taxane Sensitivity in Prostate Cancer Patients” (Giannakakou, Plymate, co-inventors)
 
Russell Zelig Szmulewitz
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Exelixis; Janssen Oncology; Merck
Research Funding - Abbvie; Astellas Pharma; Incyte; Janssen Oncology; Macrogenics
Patents, Royalties, Other Intellectual Property - Patent licensed by University of Chicago of which I am co-inventor to Corcept Therapeutics for combination AR/GR inhibition in prostate cancer
Travel, Accommodations, Expenses - Corcept Therapeutics
 
Daniel Costin Danila
Honoraria - Angle; Astellas Scientific and Medical Affairs Inc; Bayer; Xian-Janssen Pharmaceutical
Consulting or Advisory Role - Angle; Bayer
Research Funding - Genentech; Janssen Research & Development (Inst); Prostate Cancer Foundation
Patents, Royalties, Other Intellectual Property - GENE EXPRESSION PROFILE ASSOCIATED WITH PROSTATE CANCER
Travel, Accommodations, Expenses - American Austrian Open Medical Institute; Angle; Bayer; Cambridge Healthtech Institute; Global Technology Community; Oncology Education; Prostate Cancer Foundation; Xian-Janssen Pharmaceutical
 
Patrick Healy
No Relationships to Disclose
 
Monika Anand
No Relationships to Disclose
 
Colin Rothwell
No Relationships to Disclose
 
John Silberstein
No Relationships to Disclose
 
Giuseppe Galletti
No Relationships to Disclose
 
Jason Somarelli
No Relationships to Disclose
 
Santosh Gupta
No Relationships to Disclose
 
Simon Gregory
Consulting or Advisory Role - Bayer
Research Funding - Janssen (Inst)
 
Howard I. Scher
Leadership - Asterias Biotherapeutics
Consulting or Advisory Role - Clovis Oncology; Ferring; Janssen Research & Development; Onclive; Physician Education Resource; Sanofi; WIRB-Copernicus Group
Research Funding - Illumina (Inst); Innocrin Pharma (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Asterias Biotherapeutics; Onclive; Physician Education Resource; Sanofi; WIRB-Copernicus Group
 
Ryan Dittamore
Employment - Epic Sciences
Leadership - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
Patents, Royalties, Other Intellectual Property - Patents Pending
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Dendreon; Endocyte; Genentech; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Sanofi; Tolmar
Speakers' Bureau - Amgen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Immunomedics; Sanofi
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Daniel J. George
Honoraria - Axess Oncology; Bayer; BIOPHARM; Dendreon; Medivation; Novartis; Sanofi
Consulting or Advisory Role - Acceleron Pharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Celgene; Dendreon; Exelixis; Genentech; GlaxoSmithKline; Innocrin Pharma; Janssen; Medivation; Merck Sharp & Dohme; Myovant Sciences; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); Innocrin Pharma; Janssen Oncology (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Genentech/Roche; Medivation; Merck; Pfizer